The current Phase 2 clinical trials have the capacity to create significant value for our shareholders not only on their stand-alone merits in the pharmaceutical development chain, but also by supporting the commercialization of Satipharm’s Gelpell products, which have been exclusively licensed to Phytotech Therapeutics in the Rx field on a royalty free basis, for the international medical cannabis and dietary supplement markets.
The current Phase 2 clinical trials have the capacity to create...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
